NCT00718666 - The Long-term Antibody Persistence of GSK Biologicals' Meningococcal Vaccine GSK134612 in Healthy Toddlers | Biotech Hunter

Enrollment

387

Participants

Timeline

Start Date

October 20, 2008

Primary Completion Date

November 13, 2013

Study Completion Date

March 28, 2014

Conditions

Infections, Meningococcal

Interventions

BIOLOGICAL

Meningococcal vaccine GSK134612

One dose, as intramuscular injection

Trial Locations (14)

GSK Investigational Site, Lakewood

GSK Investigational Site, Canton

GSK Investigational Site, Benton

GSK Investigational Site, Little Rock

GSK Investigational Site, Amarillo

GSK Investigational Site, Wheat Ridge

GSK Investigational Site, Littleton

GSK Investigational Site, Littleton

GSK Investigational Site, Westminster

GSK Investigational Site, Antioch

GSK Investigational Site, Fremont

GSK Investigational Site, Hayward

GSK Investigational Site, Santa Rosa

GSK Investigational Site, Vacaville